Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder

W. Oslin, David; G. Lynch, Kevin; Shih, Mei‐Chiung; Ingram, Erin; O. Wray, Laura; R. Chapman, Sara; R. Kranzler, Henry; Gelernter, Joel; M. Pyne, Jeffrey; Stone, Annjanette; L. DuVall, Scott; Soleymani Lehmann, Lisa; E. Thase, Michael; Aslam, Muhammad; L. Batki, Steven; M. Bjork, James; C. Blow, Frederic; A. Brenner, Lisa; Chen, Peijun; Desai, Shivan; Dieperink, Eric; C. Fears, Scott; A. Fuller, Matthew; S. Goodman, Courtney; P. Graham, David; L. Haas, Gretchen; B. Hamner, Mark; Helstrom, Amy; A. Hurley, Robin; Icardi, Michael; Jurjus, George; M. Kilbourne, Amy; Kreyenbuhl, Julie; J. Lache, Daniel; P. Lieske, Steven; A. Lynch, Julie; J. Meyer, Laurence; Montalvo, Cristina; Muralidhar, Sumitra; J. Ostacher, Michael; Y. Paschall, Gayla; N. Pfeiffer, Paul; Prieto, Susana; M. Przygodzki, Ronald; Ranganathan, Mohini; Rodriguez‐Suarez, Mercedes; Roggenkamp, Hannah; A. Schichman, Steven; S. Schneeweis, John; A. Simonetti, Joseph; R. Steinhauer, Stuart; Suppes, Trisha; A. Umbert, Maria; L. Vassy, Jason; Voora, Deepak; R. Wiechers, Ilse; E. Wood, A.

doi:10.1001/jama.2022.9805

Public

Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder

Published in JAMA • Jul 12, 2022

Authors:

David W. Oslin

Kevin G. Lynch

Mei‐Chiung Shih

Abstract

Importance: Selecting effective antidepressants for the treatment of major depressive disorder (MDD) is an imprecise practice, with remission rates of about 30% at the initial treatment. Objective: To determine whether pharmacogenomic testing affects antidepressant medication selection and whether s...

Subject

Medicine

Veterans Affairs

Major depressive disorder

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!